PMDD and suicidality: finally the evidence for what millions know to be a lived experience

[trigger warning: self-harm]

In women’s health, it’s unfortunately a common experience to have data catch up to lived experience only years and decades later. A newly published systematic review has finally provided the data for what many people living with PMDD have long known: suicidality is not a rare or fringe experience in this condition. It is common, serious, and still almost entirely unaddressed by the research community when it comes to treatment.

The review, published 27 April 2026 in Administration and Policy in Mental Health and Mental Health Services Research, was led by Eliza Zhitnik and colleagues at the University of Massachusetts Amherst. It is one of the most comprehensive analyses of this topic to date.

What the researchers did

Zhitnik et al. (2026) searched three major academic databases (PubMed, PsycInfo, and CENTRAL) for primary empirical studies published in English from 2013 onwards. Why 2013? This is when PMDD was formally recognized as a psychiatric diagnosis in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) - prior to that it would have commonly been misdiagnosed (a problem that remains largely unsolved) as bipolar disorder, borderline personality disorder, and/or depression. Eighteen studies met the inclusion criteria, collectively covering approximately 2.6 million people.

The team used the Mixed Methods Appraisal Tool (MMAT) to evaluate the quality of each study. It is worth zooming into one mechanistic aspect: 70% of included studies had methodological issues flagged by this appraisal process. That does not mean the evidence is wrong, but it does mean this is an evidence base that is still developing, and one that needs more rigorous, consistently designed research; unfortunately quite common across womens health research.

What they found

Eight distinct suicidality-related indicators emerged across the studies, all of them significantly associated with PMDD or premenstrual disorders more broadly. The prevalence figures vary widely, in part because different studies measured different things at different points in the cycle, but even at the lower end, they are striking:

• General suicidality: 16% to 30.47%
• Suicidal ideation (thoughts of suicide): 26% to 86%
• Suicide planning: 11.5% to 41.5%
• Suicide attempts: 7.1% to 60.7%

The variation across these ranges is real, and it reflects a substantive problem in the field: there is no consistent definition of PMDD being used across studies, and no consistent definition of what counts as a suicidality-related outcome. That inconsistency makes it hard to compare findings or build cumulative knowledge.

Even so, the picture that emerges is unambiguous. Whether you look at the lower bounds or the upper bounds, people with PMDD are experiencing suicidal thoughts and behaviors at rates that demand serious clinical and research attention.

Risk factors identified

The review identified several factors associated with higher rates of suicidality in people with PMDD. These included:

• The presence of other psychiatric conditions, particularly major depressive disorder
• Personality characteristics involving impulsivity, aggression, and persistent feelings of hopelessness
• Hormonal factors, aligning with existing thinking about the role of hormone sensitivity in PMDD’s underlying mechanisms

None of this means that any of these factors cause suicidality, or that having them means someone will experience suicidal thoughts. But it does help identify where clinical attention and support may be most needed.

The gap that matters most

Perhaps the most important finding in the entire review is that not a single study was identified that evaluated treatments specifically targeting suicidality in people with PMDD.

It means that despite a growing body of evidence confirming suicidality as a real and significant feature of this condition, clinicians have no treatment-specific evidence to draw on for this aspect of PMDD. Research has established the problem; it has not yet begun to build the solutions.

This finding sits within a broader conversation in the field. Gordon et al. (2025), writing in The Lancet Psychiatry on behalf of the International Association for Premenstrual Disorders (IAPMD), argued that suicidality should be formally considered for inclusion in PMDD’s diagnostic criteria. This is a step that could help ensure it is screened for and taken seriously in clinical settings. Zhitnik et al.'s review adds weight to that argument, and underscores the urgency of developing and testing targeted interventions.

Why this research matters

For people living with PMDD, the findings in this review may feel validating. They are confirmation that what you have experienced, or feared, or searched for words to describe, is real and documented. The science, however imperfect in its current state, is catching up.

For the research community, this review is a clear signal that consistent definitions, higher-quality studies, and, critically, intervention research are all urgently needed. Knowing that suicidality is common in PMDD is only the first step. Understanding how to help is the work that still needs to be done.

Samphire will continue to track this research as it develops.

---

If you are struggling right now: You are not alone, and support is available.

• In the UK, contact the Samaritans on 116 123 (free, 24 hours).
• In the US, call or text 988 (Suicide and Crisis Lifeline, free, 24 hours).
• In other countries, the International Association for Suicide Prevention maintains a directory of crisis centers at https://www.iasp.info/resources/Crisis_Centres/.